All sectors
Healthcare Stocks
70 NSE-listed healthcare companies. Prices refresh daily after market close. Click any "Buy" to open a free demat account.
Large Cap Healthcare
14 stocks
| Symbol | Company | Price | |
|---|---|---|---|
| ABBOTINDIA | Abbott India Ltd. | ₹25,415 | Buy |
| ACUTAAS | Acutaas Chemicals Ltd. | ₹2,676.4 | Buy |
| AJANTPHARM | Ajanta Pharmaceuticals Ltd. | ₹2,900.7 | Buy |
| ALKEM | Alkem Laboratories Ltd. | ₹5,360.5 | Buy |
| ANTHEM | Anthem Biosciences Ltd. | ₹764.2 | Buy |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd | ₹7,737.5 | Buy |
| ASTERDM | Aster DM Healthcare Ltd. | ₹744.85 | Buy |
| AUROPHARMA | Aurobindo Pharma Ltd. | ₹1,376 | Buy |
| BIOCON | Biocon Ltd. | ₹360.6 | Buy |
| BLUEJET | Blue Jet Healthcare Ltd. | ₹475.85 | Buy |
| CIPLA | Cipla Ltd | ₹1,335 | Buy |
| DIVISLAB | Divi's Laboratories Ltd | ₹6,619.5 | Buy |
| DRREDDY | Dr Reddy's Laboratories Ltd | ₹1,287.2 | Buy |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd | ₹1,823.5 | Buy |
Mid Cap Healthcare
13 stocks
| Symbol | Company | Price | |
|---|---|---|---|
| CAPLIPOINT | Caplin Point Laboratories Ltd. | ₹1,736.3 | Buy |
| COHANCE | Cohance Lifesciences Ltd. | ₹470.75 | Buy |
| CONCORDBIO | Concord Biotech Ltd. | ₹1,195.2 | Buy |
| EMCURE | Emcure Pharmaceuticals Ltd. | ₹1,793.2 | Buy |
| ERIS | Eris Lifesciences Ltd. | ₹1,353.6 | Buy |
| FORTIS | Fortis Healthcare Ltd. | ₹952.9 | Buy |
| GLAND | Gland Pharma Ltd. | ₹1,815.5 | Buy |
| GLAXO | Glaxosmithkline Pharmaceuticals Ltd. | ₹2,349.9 | Buy |
| GLENMARK | Glenmark Pharmaceuticals Ltd. | ₹2,393.7 | Buy |
| GRANULES | Granules India Ltd. | ₹703.4 | Buy |
| INDGN | Indegene Ltd. | ₹533.35 | Buy |
| LALPATHLAB | Dr. Lal Path Labs Ltd. | ₹1,573.4 | Buy |
| MEDANTA | Global Health Ltd. | ₹1,171.5 | Buy |
Small Cap Healthcare
43 stocks
⚠️ Important Disclaimer: InvestingPro is not a registered investment advisor or SEBI-registered entity. Content is for educational purposes only and should not be considered personalized financial advice. Please consult a licensed financial professional before making investment decisions. Read full disclaimer →
No paid rankings
Methodology disclosed
SEBI-compliant
228+ researched articles